A study of hydroxychloroquine as post exposure prophylaxis for SARS-CoV-2 (HOPE trial)

Yonsei University Health System, Gangnam Severance Hospital0 个研究点目标入组 2,486 人开始时间: 待定最近更新: 2020年4月21日

适应症

试验速览

暂无简介。

•? A person who is classified as a contact person from a confirmed patient who has confirmed SARS-CoV-2
•? Medical staff exposed from confirmed persons in hospitals where SARS-CoV-2 infection has occurred
•? Persons exposed to COVID-19 in certain workplaces, religious groups, military outbreak
•* Subjects of study include both asymptomatic and bequest boxes as contacts of confirmed patients.

•Hypersensitivity to Chloroquine or HCQ
•Those who are contraindicated in HCQ administration according to the permission requirements, such as pregnant women, lactating women, women who may be pregnant, women with visual impairments, eye diseases such as macular disease, and patients with porphyria
•Human immunodeficiency virus (HIV) infection
•Patients with autoimmune disease (Systemic lupus erythematosus, Mixed connective tissue disease)
•Autoimmune inflammatory rheumatic diseases (AIIRD)-Ankylosing spondylitis
•Arrhythmia, cirrhosis of Child Pugh C, chronic kidney failure with eGFR <30mL / min / 1.73m2 (non-dialysis patients)
•A person who is positive in the COVID-19 screening test before taking preventive medication

发起方

Yonsei University Health System, Gangnam Severance Hospital